


# 글로벌 제약사 파이프라인 분석

- GSK -

2022. 09.


국가신약개발사업단

• 질환별 파이프라인



질환분야	개수	비중
Infectious	42	53%
Oncology	22	28%
Immunology	8	10%
Respiratory	3	7%
Cardiovascular	1	1.25%
Hematology	1	1.25%
Dermatology	1	1.25%
Neuroscience	1	1.25%
<b>합계</b>	<b>79개</b>	<b>100%</b>

• 물질별 파이프라인



물질	개수	비중
Antibody	23	29%
Vaccine	21	27%
Small molecules	20	25%
ADC	5	6%
Cell Therapy	3	4%
N/A(Not Applicable)	3	4%
RNA	2	2.5%
Protein	2	2.5%
<b>합계</b>	<b>79개</b>	<b>100%</b>

## • 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Infectious	Registration	GSK3536820A	Menveo		Meningococcal A, C, W, Y disease prophylaxis, adolescents	Vaccine	N/A	Conjugated-liquid formulation vaccine	Mono	-
2	Infectious	Registration	GSK4182136	Xevudy	sotrovimab	COVID-19	Antibody	SARS-Cov-2, SARS, ACE2, CD4	Anti-spike protein antibody	Mono	-
3	Infectious	Registration	GSK4353001A			COVID-19	Vaccine	N/A	Recombinant protein-adjuvanted vaccine	Mono	Sanofi
4	Infectious	Registration	GSK4362620A			COVID-19	Vaccine	N/A	Recombinant protein-adjuvanted vaccine	Mono	Medicago
5	Infectious	Registration	SB209762	Priorix		Measles, mumps, rubella prophylaxis	Vaccine	N/A	Live attenuated vaccine	Mono	-
6	Infectious	Registration	SB444563	Rotarix		Rotavirus prophylaxis	Vaccine	N/A	Live attenuated, PCV free vaccine	Mono	-
7	Dermatology	Phase 3	GSK2330672		linerixibat	Cholestatic pruritus in primary biliary cholangitis	Small molecules	IBAT	IBAT inhibitor	Mono	-
8	Hematology	Phase 3	GSK1278863	Duvroq	daprodustat	Anaemia associated with chronic renal disease	Small molecules	EGLN	EGLN inhibitor	Mono	-
9	Immunology	Phase 3	GSK3196165		otilimab	Rheumatoid arthritis	Antibody	GM-CSF	GM-CSF inhibitor	Mono	-
10	Immunology	Phase 3	GSK4527223		latozinemab		Antibody	Sortilin	Sortilin inhibitor	Mono	Alector
11	Infectious	Phase 3	GSK2140944		gepotidacin	Uncomplicated UTI (acute cystitis)	Small molecules	TOP2	TOP2 inhibitor	Mono	-
12	Infectious	Phase 3	GSK2140944		gepotidacin	Urogenital gonorrhoea	Small molecules	TOP2	TOP2 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
13	Infectious	Phase 3	GSK3536819A			Meningococcal A, C, W, Y disease prophylaxis, adolescents	Vaccine	N/A	Recombinant protein conjugated vaccine	Mono	-
14	Infectious	Phase 3	GSK3536829A	Bexsero		Meningococcal B disease prophylaxis, infants	Vaccine	N/A	Recombinant protein vaccine	Mono	-
15	Infectious	Phase 3	GSK3844766A			Respiratory syncytial virus prophylaxis, older adult	Vaccine	N/A	Recombinant protein adjuvanted vaccine	Mono	-
16	Infectious	Phase 3	GSK4182136	Xevudy	sotrovimab	COVID-19 hospitalized	Antibody	SARS-Cov-2, SARS, ACE2, CD4	Anti-spike protein antibody	Mono	-
17	Infectious	Phase 3	GSK4382371A	SKYCovione		COVID-19	Vaccine	SARS-Cov-2	Recombinant protein nanoparticle-adjuvanted vaccine	Mono	SK Bioscience
18	Oncology	Phase 3	GSK2857916	Blenrep	belantamab mafodotin	3L multiple myeloma	ADC	BCMA	Cytotoxic to cells expressing BCMA	Mono	-
19	Oncology	Phase 3	GSK2857916	Blenrep	belantamab mafodotin	2L multiple myeloma combination with Pomalyst+dexamethasone	ADC	BCMA	Cytotoxic to cells expressing BCMA	Combination	-
20	Oncology	Phase 3	GSK2857916	Blenrep	belantamab mafodotin	2L multiple myeloma combination with Velcade+dexamethasone	ADC	BCMA	Cytotoxic to cells expressing BCMA	Combination	-
21	Oncology	Phase 3	GSK3985771	Zejela	niraparib	1L maintenance ovarian cancer combination with Jemperli	Small molecules	PARP 1/2	PARP 1/2 inhibitor	Combination	-
22	Oncology	Phase 3	GSK3985771	Zejela	niraparib	1L maintenance NSCLC combination with pembrolizumab	Small molecules	PARP 1/2	PARP 1/2 inhibitor	Combination	-
23	Oncology	Phase 3	GSK3985771	Zejela	niraparib	Pre-metastatic, select biomarker population breast cancer	Small molecules	PARP 1/2	PARP 1/2 inhibitor	Mono	-
24	Oncology	Phase 3	GSK4057190	Jemperli	dostarlimab	1L endometrial cancer	Antibody	PD-1	PD-1 antagonist	Mono	AnaptysBio

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
25	Oncology	Phase 3	GSK4057190	Jemperli	dostarlimab	1L endometrial cancer combination with niraparib	Antibody	PD-1	PD-1 antagonist	Combination	AnaptysBio
26	Respiratory	Phase 3	GSK3511294		depemokimab	Asthma	Antibody	IL-5	IL-5 antagonist	Mono	-
27	Respiratory	Phase 3	SB240563	Nucala	mepolixumab	COPD	Antibody	IL-5	IL-5 antagonist	Mono	-
28	Immunology	Phase 2	GSK4527223		latozinemab	Amyotrophic lateral sclerosis	Antibody	Sortilin	Sortilin inhibitor	Mono	Alector
29	Immunology	Phase 2	GSK4527223			Frontotemporal dementia	Antibody	Sortilin	Sortilin inhibitor	Mono	Alector
30	Infectious	Phase 2	GSK3036656			Tuberculosis	Small molecules	LARS	LARS inhibitor	Mono	-
31	Infectious	Phase 2	GSK3228836		bepirovirsen	Hepatitis B	RNA	N/A	ASO	Mono	Ionis
32	Infectious	Phase 2	GSK3228836		bepirovirsen	Hepatitis B sequential combination with Pegylated Interferon	RNA	N/A	ASO	Combination	Ionis
33	Infectious	Phase 2	GSK3437949A			Malaria prophylaxis	Vaccine	N/A	Recombinant protein-adjuvanted vaccine	Mono	-
34	Infectious	Phase 2	GSK3528869A			Chronic hepatitis B infections	Vaccine	N/A	Prime-boost with viral vector vaccines co- or sequentially administered with adjuvanted recombinant proteins vaccine	Mono	-
35	Infectious	Phase 2	GSK3640254			HIV	Small molecules	N/A	HIV maturation inhibitor	Mono	-
36	Infectious	Phase 2	GSK3878858A			Primary and recurrent soft-skin-tissue infections caused by S. aureus	Vaccine	N/A	Recombinant protein-bioconjugated- adjuvanted vaccine	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
37	Infectious	Phase 2	GSK4023393A			Meningococcal A, B, C, W, Y disease prophylaxis in adolescents	Vaccine	N/A	Recombinant protein-c onjugated vaccine	Mono	-
38	Infectious	Phase 2	GSK4069327A			Shigella diarrhea prophylaxis	Vaccine	N/A	Recombinant protein-a djuvanted vaccine	Mono	-
39	Infectious	Phase 2	GSK4178116A			varicella, 12 months of age and older	Vaccine	N/A	Live attenuated vaccine	Mono	-
40	Infectious	Phase 2	GSK4388067A			Chronic hepatitis B virus infection, >18 yrs w/o decompensated cirrhosis	Protein	N/A	Targeted immunotherapy&direct acting antiviral	Combination	-
41	Infectious	Phase 2	VH3810109			HIV	Antibody	Surface Protein gp120	Surface Protein gp120 inhibitor	Mono	Viiv Healthcare
42	Oncology	Phase 2	GSK2857916	Blenrep	belantamab mafodotin	Multiple myeloma combination with anti-cancer treatment	ADC	BCMA	Cytotoxic to cells expressing BCMA	Combination	-
43	Oncology	Phase 2	GSK3377794		letetresgene-autoleucel	2L+ synovial sarcoma and myxoid/round cell liposarcoma	Cell Therapy	CTAG1B	Cytotoxic to cells expressing CTAG1B	Mono	-
44	Oncology	Phase 2	GSK4057190	Jemperli	dostarlimab	NSCLC combination with Jemperli and docetaxel	Antibody	PD-1	PD-1 antagonist	Combination	-
45	Oncology	Phase 2	GSK4069889		cobolimab	NSCLC combination with Jemperli and docetaxel	Antibody	TIM3	TIM3 inhibitor	Combination	AnaptysBio
46	Cardiovascular	Phase 1	GSK3884464			Heart failure	N/A	N/A	N/A	Mono	-
47	Immunology	Phase 1	GSK1070806			Atopic dermatitis	Antibody	IL-18	IL-18 inhibitor	Mono	-
48	Immunology	Phase 1	GSK3858279			Osteoarthritis pain	Antibody	CCL17	CCL17 inhibitor	Mono	-
49	Immunology	Phase 1	GSK3888130			Multiple sclerosis	Antibody	IL-7	IL-7 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
37	Infectious	Phase 2	GSK4023393A			Meningococcal A, B, C, W, Y disease prophylaxis in adolescents	Vaccine	N/A	Recombinant protein-c onjugated vaccine	Mono	-
38	Infectious	Phase 2	GSK4069327A			Shigella diarrhea prophylaxis	Vaccine	N/A	Recombinant protein-a djuvanted vaccine	Mono	-
39	Infectious	Phase 2	GSK4178116A			varicella, 12 months of age and older	Vaccine	N/A	Live attenuated vaccine	Mono	-
40	Infectious	Phase 2	GSK4388067A			Chronic hepatitis B virus infection, >18 yrs w/o decompensated cirrhosis	Protein	N/A	Targeted immunotherapy&direct acting antiviral	Combination	-
41	Infectious	Phase 2	VH3810109			HIV	Antibody	Surface Protein gp120	Surface Protein gp120 inhibitor	Mono	Viiv Healthcare
42	Oncology	Phase 2	GSK2857916	Blenrep	belantamab mafodotin	Multiple myeloma combination with anti-cancer treatment	ADC	BCMA	Cytotoxic to cells expressing BCMA	Combination	-
43	Oncology	Phase 2	GSK3377794		letetresgene-autoleucel	2L+ synovial sarcoma and myxoid/round cell liposarcoma	Cell Therapy	CTAG1B	Cytotoxic to cells expressing CTAG1B	Mono	-
44	Oncology	Phase 2	GSK4057190	Jemperli	dostarlimab	NSCLC combination with Jemperli and docetaxel	Antibody	PD-1	PD-1 antagonist	Combination	-
45	Oncology	Phase 2	GSK4069889		cobolimab	NSCLC combination with Jemperli and docetaxel	Antibody	TIM3	TIM3 inhibitor	Combination	AnaptysBio
46	Cardiovascular	Phase 1	GSK3884464			Heart failure	N/A	N/A	N/A	Mono	-
47	Immunology	Phase 1	GSK1070806			Atopic dermatitis	Antibody	IL-18	IL-18 inhibitor	Mono	-
48	Immunology	Phase 1	GSK3858279			Osteoarthritis pain	Antibody	CCL17	CCL17 inhibitor	Mono	-
49	Immunology	Phase 1	GSK3888130			Multiple sclerosis	Antibody	IL-7	IL-7 inhibitor	Mono	-



No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
50	Immunology	Phase 1	GSK3915393			Celiac disease	Small molecules	TG2	TG2 inhibitor	Mono	-
51	Infectious	Phase 1	BH4004280			HIV	N/A	N/A	HIV capsid protein inhibitor	Mono	-
52	Infectious	Phase 1	BVL-GSK098			Tuberculosis	Small molecules	EthR	EthR inhibitor	Mono	BioVersys
53	Infectious	Phase 1	GSK1265744		cabotegravir	HIV	Small molecules	HIV integrase	HIV integrase inhibitor	Mono	Viiv Healthcare
54	Infectious	Phase 1	GSK2556286			Tuberculosis	Small molecules	N/A	Mtb cholesterol dependent inhibitor	Mono	-
55	Infectious	Phase 1	GSK2904545A			Primary C. Diff disease and for recurrences	Vaccine	N/A	Recombinant protein-adjuvanted vaccine	Mono	-
56	Infectious	Phase 1	GSK3186899			Visceral leishmaniasis	Small molecules	CRK-12	CRK-12 inhibitor	Mono	-
57	Infectious	Phase 1	GSK3494245			Visceral leishmaniasis	Small molecules	Proteasome	Proteasome inhibitor	Mono	-
58	Infectious	Phase 1	GSK3882347			uncomplicated UTI	Small molecules	FimH	FimH antagonist	Mono	Fimbrion Therapeutics
59	Infectious	Phase 1	GSK3923868			Viral COPD exacerbations	Small molecules	PI4K	PI4K beta inhibitor	Mono	-
60	Infectious	Phase 1	GSK3943104A			Genital Herpes, adults	Vaccine	N/A	Recombinant protein-adjuvanted vaccine	Mono	-
61	Infectious	Phase 1	GSK3993129A			Cytomegalovirus infection prophylaxis	Vaccine	N/A	Recombinant subunit-adjuvanted vaccine	Mono	-
62	Infectious	Phase 1	GSK4182137			COVID-19	Antibody	Novel corona virus spike glycoprotein	Novel corona virus spike glycoprotein inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
63	Infectious	Phase 1	GSK4382276A			Influenza, adults	Vaccine	N/A	mRNA vaccine	Mono	-
64	Infectious	Phase 1	GSK4396687A			COVID-19, 12 yrs and above	Vaccine	N/A	mRNA vaccine	Mono	-
65	Infectious	Phase 1	GSK4429016A			Klebsiella pneumoniae prophylaxis	Vaccine	N/A	Recombinant protein-bio conjugated-adjuvanted vaccine	Mono	-
66	Infectious	Phase 1	VH3739937			HIV	Small molecules	N/A	HIV maturation inhibitor	Mono	Viiv Healthcare
67	Infectious	Phase 1	VIR-2482			Influenza	Antibody	N/A	N/A	Mono	Vir Biotechnology
68	Metabolic	Phase 1	GSK4532900			Non-alcoholic steatohepatitis (NASH)	N/A	HSD17B13	HSD17B13 silencer	Mono	-
69	Neuroscience	Phase 1	GSK4527226			Neurodegenerative disease	Antibody	Sortilin	Sortilin inhibitor	Mono	Alector
70	Oncology	Phase 1	GSK2857916	Blenrep	gelatamab mafodotin	1L multiple myeloma combination with Velcade, Revlimid and dexamethasone	ADC	BCMA	Cytotoxic to cells expressing BCMA	Combination	-
71	Oncology	Phase 1	GSK3537142			Cancer	Protein	NY-ESO, CD3	NY-ESO inhibitor, CD3 agonist	Mono	-
72	Oncology	Phase 1	GSK3745417			Cancer	Small molecules	STING	STING agonist	Mono	-
73	Oncology	Phase 1	GSK3845097			Cancer	Cell Therapy	NY-ESO	Cytotoxic to cells expressing NY-ESO	Mono	-
74	Oncology	Phase 1	GSK3901961			Cancer	Cell Therapy	NY-ESO	Cytotoxic to cells expressing NY-ESO	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
75	Oncology	Phase 1	GSK4074386			Cancer	Antibody	LAG-3	LAG-3 inhibitor	Mono	-
76	Oncology	Phase 1	GSK4362676			Cancer	Small molecules	MAT2A	MAT2A inhibitor	Mono	Ideaya Biosciences
77	Oncology	Phase 1	GSK4381562			Cancer	Antibody	PVRIG	PVRIG antagonist	Mono	Surface Oncology
78	Oncology	Phase 1	GSK-4428859			Cancer	Antibody	TIGIT	TIGIT antagonist	Mono	-
79	Oncology	Phase 1	GSK6097608			Cancer	Antibody	CD96	CD96 antagonist	Mono	-
75	Oncology	Phase 1	GSK4074386			Cancer	Antibody	LAG-3	LAG-3 inhibitor	Mono	-
76	Oncology	Phase 1	GSK4362676			Cancer	Small molecules	MAT2A	MAT2A inhibitor	Mono	Ideaya Biosciences
77	Oncology	Phase 1	GSK4381562			Cancer	Antibody	PVRIG	PVRIG antagonist	Mono	Surface Oncology
78	Oncology	Phase 1	GSK-4428859			Cancer	Antibody	TIGIT	TIGIT antagonist	Mono	-
79	Oncology	Phase 1	GSK6097608			Cancer	Antibody	CD96	CD96 antagonist	Mono	-

자료: GSK 홈페이지, BioCentury, GlobalData